Brief: Inventiva Receives A 4 Million Euros Milestone Payment From AbbVie

Inventiva SA

01/02/2022 06:43

Feb 1 (Reuters) - INVENTIVA  IVAA.PA :
    * ANNOUNCED ON MONDAY IT RECEIVED A EUR 4 MLN MILESTONE
PAYMENT
FROM ABBVIE FOR CEDIROGANT PHASE IIB INITIATION
    * IT FOLLOWS THE INCLUSION OF THE FIRST PATIENT WITH
PSORIASIS IN
THE ONGOING PHASE IIB CLINICAL TRIAL WITH CEDIROGANT
(ABBV-157)1, AN ORAL RORG INVERSE AGONIST JOINTLY DISCOVERED BY
INVENTIVA AND ABBVIE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    * THIS COLLABORATION WITH ABBVIE ENABLES INVENTIVA TO
RECEIVE
PAYMENTS UPON THE ACHIEVEMENT OF CLINICAL, REGULATORY AND
COMMERCIAL MILESTONES, AS WELL AS TIERED ROYALTIES ON PRODUCT
SALES, FROM MID SINGLE-DIGIT TO LOW DOUBLE-DIGIT

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNEbq2MTS
 Further company coverage:  IVAA.PA   ABBV.N 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))